secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2024-01-09T23:59:59+00:00
Accession:  0001104659-24-002401
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar announces positive pivotal trial data for iopofosine I 131 in WM
--------------------------------------------------------------------------

- CLOVER-WaM study met primary endpoint with 61% major response rate (p<0.0001), exceeding 20% statistical hurdle.
- Overall response rate of 75.6% and 100% disease control in heavily pretreated, BTKi-refractory WM patients.
- Median duration of response not yet reached at median 8-month follow-up; 76% remain progression-free.
- No treatment-related discontinuations or deaths; Grade 3+ cytopenias manageable with no bleeding or febrile neutropenia beyond 2%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924002401/0001104659-24-002401-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924002401/tm242431d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-002401

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer